Biggest News Aggregation in the World
📰 Cell Avidity News

Page 3 - Cell Avidity News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Cell Avidity. Real-time updates on events, politics, business and more.

LUMICKS: New study published in Translational Medicine highlights cell avidity's power as a functional biomarker for improved CAR-T design in preventing tumor escape

AMSTERDAM, Jan. 25, 2022 /PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced that research findings from a consortium, led by researchers at Cancer Center
Noord Holland Kostenloser Wertpapierhandel Joshua Young Maria Themeli Andrea Candelli Kassandra Barbetsea

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

LUMICKS Further Strengthens Leadership Team, Appoints Joshua Young as Vice President of Investor Relations, Communications and Strategy

AMSTERDAM, Oct. 27, 2021 /PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced it has appointed Joshua Young to lead the company's Investor Relations, Communications
United States Boston College Noord Holland Kostenloser Wertpapierhandel Joshua Young Olivier Heyning

Regensburg Center for Interventional Immunology adopts LUMICKS' z-Movi® Cell Avidity Analyzer

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric ...
Noord Holland Erwin Peterman Hinrich Abken Iddo Heller Andrea Candelli Kassandra Barbetsea

Lumicks Raises $93M in Series D Financing

Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healt...
Noord Holland Erwin Peterman Iddo Heller Olivier Heyning Gijs Wuite T Rowe Price Associates

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science